Table 3 IORT studiesfor bladder cancer
Reference | N. pts | Stage | EBRT | Treatment | Local control (5 years) | Overall survival 5-years | Toxicity |
|---|---|---|---|---|---|---|---|
Hallemeier [35] | 11 | Local recurrence | Neoadjuvant | Surgery + IORT (12.5 Gy) | 51% | 16% | NA |
Koning [36] | 1040 | T1-T2 | Neoadjuvant | surgery, Ir-192 (25–40 Gy) | 75% | 62% | Fistula 24, ulcers/necroses 144 |
van Onna [37] | 111 | T1-T2 | Neoadjuvant | Ir-192 (40 Gy) | NA | 70% | Fistula 5 GU 5 |
van der Steen-Banasik [38] | 76 | T1-T2 | Neoadjuvant | Cs-137, Ir-192 (30–60 Gy) | 70% | 57% | NA |
Blank [39] | 122 | T1-T2-T3 | Neoadjuvant | Ir-192 (20–70 Gy) | 76% | 73% | GU 5 |
Nieuwenhuijzen [40] | 108 | T1-T2 | Neoadjuvant | Ir-192 | 73% | 62% | NA |
De Crevoisier [41] | 58 | T1-T2-T3 | Neoadjuvant | surgery, Ir-192 (60 Gy) | 65% | 60% | 5 major late toxicities |
Gerard [42] | 27 | T2, T3 | No | Surgery + IORT | 85% | 53% | NA |
Pernot [43] | 82 | T1, T2, T3, T4, Tx | Neoadjuvant | surgery Ir-192 (30–50 Gy | 78% | 73% | 7 late toxcities ≥ G3 |
Calvo [44] | 40 | T2, T3, T4 | Neoadjuvant | surgery + IORT (15 Gy) | NA | 68% | NA |
Rozan [45] | 205 | T1-T2-T3 | Neoadjuvant | surgery Ir-192 (30–50 Gy | NA | 77.4% T1, 62.9% T2, 46.8% T3 | haematuria, fistula, chronic cystitis 29 |
Batterman [46] | 85 | T2 | Neoadjuvant | Ra-226 | 74% | 55% | NA |
Mazeron [47] | 24 | T2 | Adjuvant | surgery, Ir-192 | 92% | 58% | NA |
van der Werf-Messing [48] | 328 | T2 | Neoadjuvant | Ra-226 | 77% | 56% | NA |
Matsumoto [49] | 28 | T2 | Adjuvant | IORT | 82% | 62% | NA |